vs
Side-by-side financial comparison of Lineage, Inc. (LINE) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Lineage, Inc. is the larger business by last-quarter revenue ($1.4B vs $708.5M, roughly 1.9× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -7.3%, a 26.3% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 3.1%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $35.0M).
Norwegian Cruise Line Holdings (NCLH) is a holding company that is based in the United States and domiciled in Bermuda. It operates three cruise lines as wholly owned subsidiaries: Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. With its subsidiaries combined, it is the third-largest cruise operator in the world. It is a publicly traded company listed on the New York Stock Exchange.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
LINE vs MEDP — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $708.5M |
| Net Profit | $-100.0M | $135.1M |
| Gross Margin | 32.3% | — |
| Operating Margin | 2.5% | 21.6% |
| Net Margin | -7.3% | 19.1% |
| Revenue YoY | 3.1% | 32.0% |
| Net Profit YoY | 79.4% | 15.5% |
| EPS (diluted) | $-0.44 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $708.5M | ||
| Q3 25 | $1.4B | $659.9M | ||
| Q2 25 | $1.4B | $603.3M | ||
| Q1 25 | $1.3B | $558.6M | ||
| Q4 24 | $1.3B | $536.6M | ||
| Q3 24 | $1.3B | $533.3M | ||
| Q2 24 | $1.3B | $528.1M | ||
| Q1 24 | $1.3B | $511.0M |
| Q4 25 | — | $135.1M | ||
| Q3 25 | $-100.0M | $111.1M | ||
| Q2 25 | $-6.0M | $90.3M | ||
| Q1 25 | $0 | $114.6M | ||
| Q4 24 | $-71.0M | $117.0M | ||
| Q3 24 | $-485.0M | $96.4M | ||
| Q2 24 | $-68.0M | $88.4M | ||
| Q1 24 | $-40.0M | $102.6M |
| Q4 25 | — | — | ||
| Q3 25 | 32.3% | — | ||
| Q2 25 | 31.9% | — | ||
| Q1 25 | 32.2% | — | ||
| Q4 24 | 32.3% | — | ||
| Q3 24 | 32.8% | — | ||
| Q2 24 | 33.4% | — | ||
| Q1 24 | 33.4% | — |
| Q4 25 | — | 21.6% | ||
| Q3 25 | 2.5% | 21.5% | ||
| Q2 25 | 1.7% | 20.9% | ||
| Q1 25 | 4.3% | 20.3% | ||
| Q4 24 | -1.6% | 23.4% | ||
| Q3 24 | -38.6% | 21.1% | ||
| Q2 24 | 5.5% | 19.9% | ||
| Q1 24 | 7.6% | 20.4% |
| Q4 25 | — | 19.1% | ||
| Q3 25 | -7.3% | 16.8% | ||
| Q2 25 | -0.4% | 15.0% | ||
| Q1 25 | — | 20.5% | ||
| Q4 24 | -5.3% | 21.8% | ||
| Q3 24 | -36.3% | 18.1% | ||
| Q2 24 | -5.1% | 16.7% | ||
| Q1 24 | -3.0% | 20.1% |
| Q4 25 | — | $4.65 | ||
| Q3 25 | $-0.44 | $3.86 | ||
| Q2 25 | $-0.03 | $3.10 | ||
| Q1 25 | $0.01 | $3.67 | ||
| Q4 24 | $-0.52 | $3.67 | ||
| Q3 24 | $-2.44 | $3.01 | ||
| Q2 24 | $-0.46 | $2.75 | ||
| Q1 24 | $-0.28 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $497.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $8.4B | $459.1M |
| Total Assets | $19.2B | $2.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $497.0M | ||
| Q3 25 | — | $285.4M | ||
| Q2 25 | — | $46.3M | ||
| Q1 25 | — | $441.4M | ||
| Q4 24 | $173.0M | $669.4M | ||
| Q3 24 | $409.0M | $656.9M | ||
| Q2 24 | $73.0M | $510.9M | ||
| Q1 24 | — | $407.0M |
| Q4 25 | — | $459.1M | ||
| Q3 25 | $8.4B | $293.6M | ||
| Q2 25 | $8.6B | $172.4M | ||
| Q1 25 | $8.6B | $593.6M | ||
| Q4 24 | $8.6B | $825.5M | ||
| Q3 24 | $9.0B | $881.4M | ||
| Q2 24 | $4.9B | $763.6M | ||
| Q1 24 | $5.6B | $671.5M |
| Q4 25 | — | $2.0B | ||
| Q3 25 | $19.2B | $1.8B | ||
| Q2 25 | $19.4B | $1.6B | ||
| Q1 25 | $18.8B | $1.9B | ||
| Q4 24 | $18.7B | $2.1B | ||
| Q3 24 | $19.3B | $2.1B | ||
| Q2 24 | $18.8B | $1.9B | ||
| Q1 24 | — | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0M | $192.7M |
| Free Cash FlowOCF − Capex | $35.0M | $188.1M |
| FCF MarginFCF / Revenue | 2.5% | 26.6% |
| Capex IntensityCapex / Revenue | 14.2% | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $192.7M | ||
| Q3 25 | $230.0M | $246.2M | ||
| Q2 25 | $258.0M | $148.5M | ||
| Q1 25 | $139.0M | $125.8M | ||
| Q4 24 | — | $190.7M | ||
| Q3 24 | $186.0M | $149.1M | ||
| Q2 24 | $155.0M | $116.4M | ||
| Q1 24 | $105.0M | $152.7M |
| Q4 25 | — | $188.1M | ||
| Q3 25 | $35.0M | $235.5M | ||
| Q2 25 | $95.0M | $142.4M | ||
| Q1 25 | $-12.0M | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | $33.0M | $138.5M | ||
| Q2 24 | $-31.0M | $103.5M | ||
| Q1 24 | $-42.0M | $147.2M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | 2.5% | 35.7% | ||
| Q2 25 | 7.0% | 23.6% | ||
| Q1 25 | -0.9% | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | 2.5% | 26.0% | ||
| Q2 24 | -2.3% | 19.6% | ||
| Q1 24 | -3.2% | 28.8% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | 14.2% | 1.6% | ||
| Q2 25 | 12.1% | 1.0% | ||
| Q1 25 | 11.7% | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | 11.5% | 2.0% | ||
| Q2 24 | 13.9% | 2.4% | ||
| Q1 24 | 11.1% | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 2.22× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.63× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.32× | ||
| Q1 24 | — | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LINE
| Warehousing Operations | $883.0M | 64% |
| Other | $308.0M | 22% |
| Warehouse Lease | $60.0M | 4% |
| Food Sales | $52.0M | 4% |
| E Commerce And Other | $46.0M | 3% |
| Railcar Lease | $23.0M | 2% |
| Service Other | $5.0M | 0% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
